Adaptive versus conventional radiotherapy: comparing patient-reported side effects for prostate cancer
Official title: Prospective Clinical Study Comparing Patient-reported Outcomes Measurements (PROMS) After Adaptive or Conventional Radiotherapy in Prostate Cancer
Run by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · NCT07245745 · Data updated 2026-11-12
This study tests whether adaptive radiotherapy causes fewer bowel, bladder, and overall side effects than conventional radiotherapy in men receiving curative treatment for prostate cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 188 (estimated) |
| Sponsor | Cliniques universitaires Saint-Luc- Université Catholique de Louvain Academic / other |
| Locations | 1 site (Brussels) |
| Status | Recruiting |
| Started | January 13, 2026 |
| Main results expected | March 31, 2029 |
| Study ends | March 31, 2029 |
| Registry record updated | March 16, 2026 |
| Trial ID | NCT07245745 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Men with prostate cancer referred for curative-intent radiotherapy who are age 18 or older, ECOG 0-1, proficient in French, English, or Dutch, and able and willing to use the Noona e-health app are ideal candidates.
✕Probably not a fit
Patients with prior pelvic radiotherapy, prior treatment for rectal or bladder cancer, cognitive impairment, or no access/ability to use the Noona app are excluded and unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective study compares patient-reported outcome measures (PROMs) after adaptive radiotherapy (ART) delivered on the Ethos platform versus conventional radiotherapy on the Halcyon platform for prostate cancer. Participants complete regular PROMs and toxicity reporting via the Noona e-health application to capture gastrointestinal, genitourinary, and general side effects and their duration. The trial also correlates reported symptoms with dosimetric data to see if differences in delivered dose to organs at risk explain clinical outcomes. Patients are enrolled at Cliniques universitaires Saint‑Luc (Brussels and Ottignies) and must be able and willing to use the Noona app during and after treatment.
Why it matters
Potential benefit: If successful, ART could reduce the frequency and duration of bowel and urinary side effects from prostate radiotherapy, improving patients' quality of life.
How similar studies have gone: Early feasibility and dosimetric studies of adaptive radiotherapy have shown reduced dose to organs at risk and suggested possible toxicity reductions, but randomized or definitive evidence in prostate cancer remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with prostate cancer referred for curative-intent radiotherapy * Male patients ≥ 18 years old * ECOG performance status 0-1 * Patients willing to use an e-health application * Patients capable of using an e-health application * Proficient in French, English, or Dutch * No prior history of treatment for rectal or bladder cancer * No prior history of pelvic radiotherapy Exclusion Criteria: * Cognitive impairment * ECOG ≥ 2 * History of treatment for rectal or bladder cancer * History of pelvic radiotherapy * No access to the Noona application on a smartphone or computer
Where it's running
-
Cliniques universitaires Saint-Luc
Brussels, Belgium Recruiting
Study contacts
- Principal investigator: Heylen Sofie, MD — Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Study coordinator: Heylen Sofie, MD
- Email: sofie.heylen@saintluc.uclouvain.be
- Phone: 027648191
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
-
PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer
This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.
-
Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer
This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.
-
Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer
This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.
-
Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence
This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.
-
Lutetium-177 Ludotadipep for advanced prostate cancer
This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.